Study S001460

Study 110933: Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT02284009
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 67
Start: 2014-10-10
Primary completion: 2017-10-18
Lead sponsor: GlaxoSmithKline
Conditions: Diabetes Mellitus, Type 1
Interventions: BIOLOGICAL:Albiglutide weekly injection; BIOLOGICAL:Placebo weekly injection; BIOLOGICAL:Insulin
Results posted: TRUE
Individual participant data sharing: YES

Registered primary outcomes

Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52 [Baseline and Week 52]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018464	Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. Pozzilli P, The Journal of clinical endocrinology and metabolism	2020	Randomized trial	PMID 32219329 DOI	cites ClinicalTrials.gov:NCT02284009; registry reference BACKGROUND:32219329